XORTX Therapeutics Inc. (XRTX) is a biopharmaceutical company that is specialized and dedicated in the development of innovative therapies designed to treat progressive kidney disease. Based in Calgary, Alberta, Canada, and founded in 2012, XORTX’s primary focus is developing drugs that treat the underlying cause of disease rather than just the symptoms, with a pivotal concentration on renal diseases such as Polycystic Kidney Disease (PKD) and diabetic nephropathy.
The company accomplishes this through an approach that involves blocking or inhibiting specific enzymes found in the body that are linked to kidney disease. Of particular interest to XORTX is an enzyme known as xanthine oxidase that, when inhibited, can potentially reduce the progression or severity of kidney disease.
XORTX's lead development programs XRx-008, for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for COVID-19 related acute kidney injury constitute the company’s core pipeline. These drugs, currently in various stages of clinical development, offer a new approach to managing these often devastating renal diseases.
Another groundbreaking endeavor by XORTX is its development of uric acid lowering therapeutic molecules. The essence of this research lies in determining the effect of uric acid in disease progression. The company aims to slow the progression of chronic kidney diseases and diabetes by reducing high uric acid levels. For this reason, they have developed drugs like XRx-221, a uric acid-lowering compound currently undergoing preclinical development.
XRTX has been recognized for its innovative work by many stakeholders in the pharmaceutical and biotechnology fields. The company’s detailed and focused approach to drug development, in addition to its commitment to treating the root causes of disease, has placed it on the front lines of pharmaceutical innovation.
Despite being a relatively young company, XORTX has made a significant impact in the field of renal disease treatment. They have built a strong foundation with a demonstrated name for innovative and important contributions to pharmaceuticals. XORTX’s commitment to addressing critical needs in managing and treating chronic kidney disease has positioned it firmly in an important and vital role in the biotechnology industry. With ongoing trials and research, XORTX will undoubtedly continue to break new ground in the realm of kidney disease treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
XORTX Therapeutics Inc. (NASDAQ: XRTX) shares have risen by 13.55% following positive developments for its lead kidney therapy. The company has initiated contract manufacturing for its XRx-026 gout program, moving closer to planned clinical trials and a future New Drug Application. This step, combined with governance clean-up efforts like delisting from TSX Venture Exchange and clarifying finder's fees, positions XRTX as a high-volatility, catalyst-driven stock for active traders.
XORTX Therapeutics (NASDAQ:XRTX) shares climbed 16.11% after hours following the announcement of a manufacturing milestone for its lead gout program, XRx-026. The company has begun production of drug material and tablets for XORLO™, its proprietary oxypurinol formulation, to support a planned two-part clinical study. This move is a foundational step towards a future New Drug Application (NDA) submission to the FDA.
XORTX Therapeutics Inc. has begun clinical and commercial manufacturing of its drug substance and tablets for XORLO™, a proprietary oxypurinol formulation aimed at treating gout. This manufacturing effort supports the upcoming XRX-OXY-102 clinical study and is a crucial step towards securing future FDA marketing approval. The company is advancing its XRx-026 program to address the unmet medical needs in gout treatment.
XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The company is a pharmaceutical firm developing several clinically advanced products for conditions like gout, ADPKD, acute kidney injury, and diabetic nephropathy. XORTX aims to advance products targeting aberrant purine metabolism and xanthine oxidase to improve the quality of life for individuals with various diseases.